You are viewing an expired study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

Walnut Creek, California

  • Migraine Disorders

Purpose:

This is a 60 week study including a double-blind phase followed by an open-label phase.


Criteria:

Inclusion Criteria: - Frequent migraine (>=15 headache days per month) - >=4 distinct headache episodes lasting >=4 hours - >=50% of baseline headache days migraine/probable migraine days Exclusion Criteria: - Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype - Any medical condition that puts the patient at increased risk with exposure to BOTOX - Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache - Use of prophylactic headache medication within 28 days prior to week -4 - Unremitting headache lasting continuously throughout the 4-week baseline period - Known or suspected TMD - Diagnosis of fibromyalgia - Beck depression inventory score >24 at week-4 - Psychiatric problems that may have interfered with study participation


NCT ID:

NCT00168428


Primary Contact:

Study Director
Medical Director
Allergan


Backup Contact:

N/A


Location Contact:

Walnut Creek, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.